Evidence map›Paper›PMID 21925209›Full record

ArticleAntiviral research2011

GM-CSF modulates pulmonary resistance to influenza A infection.

Zvjezdana Sever-Chroneos, Aditi Murthy, Jeremy Davis, Jon Matthew Florence, Anna Kurdowska, Agnieszka Krupa, Jay W Tichelaar, Mitchell R White, Kevan L Hartshorn, Lester Kobzik and 2 more

Registry-linked trialAbstract read
In one paragraph

Article in Antiviral research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02601365 (A Phase I Study of Inhaled GM-CSF in the Treatment of Respiratory Virus-associated Severe Pneumonia), which is not on this map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02601365 phase1withdrawnnot on this mapstarted 2019, after this paper: background citation

A Phase I Study of Inhaled GM-CSF in the Treatment of Respiratory Virus-associated Severe Pneumonia

TypeinterventionalSponsorMilton S. Hershey Medical CenterRan2019 to 2019Enrolled0ConditionsAcute Respiratory Distress Syndrome, Pneumonia, Respiratory Virus InfectionArmsSargramostim 0.04 mcg/kg/dose, Sargramostim 0.2mcg/kg/dose, Sargramostim 1 mcg/kg/dose
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Innate Immunity and Influenza A Virus Pathogenesis: Lessons for COVID-19.Frontiers in cellular and infection microbiology · 2020
    Review
  18. Alveolar proteinosis due to toxic inhalation at workplace.Respiratory medicine case reports · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Zvjezdana Sever-ChroneosUniversity of Texas Health Science Center at Tyler, Center of Biomedical Research, 11937 US HWY 271, Tyler, TX 75708-3154, United States.
Aditi Murthy
Jeremy Davis
Jon Matthew Florence
Anna Kurdowska
Agnieszka Krupa
Jay W Tichelaar
Mitchell R White
Kevan L Hartshorn
Lester Kobzik
Jeffrey A Whitsett
Zissis C Chroneos
The University of Texas Health Science Center at Tyler · USBoston University · USCincinnati Children's Hospital Medical Center · USHarvard University Press · USMedical College of Wisconsin · US

Funding

Scavenger Receptors and Inhaled ParticlesR01ES011008 · NIEHS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI KOBZIK, LESTER · 2001 to 2011
$3.5M
SP-A Receptor Modulation of Macrophage PhagocytosisR01HL068127 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI CHRONEOS, ZISSIS C · 2001 to 2004
$883k
NHLBI NIH HHS R01 HL068127NIEHS NIH HHS R01 ES011008
6 · The paper itself

Abstract

Alveolar type II epithelial or other pulmonary cells secrete GM-CSF that regulates surfactant catabolism and mucosal host defense through its capacity to modulate the maturation and activation of alveolar macrophages. GM-CSF enhances expression of scavenger receptors MARCO and SR-A. The alveolar macrophage SP-R210 receptor binds the surfactant collectin SP-A mediating clearance of respiratory pathogens. The current study determined the effects of epithelial-derived GM-CSF in host resistance to influenza A pneumonia. The results demonstrate that GM-CSF enhanced resistance to infection with 1.9×10(4) ffc of the mouse-adapted influenza A/Puerto Rico/8/34 (PR8) H1N1 strain, as indicated by significant differences in mortality and mean survival of GM-CSF-deficient (GM(-/-)) mice compared to GM(-/-) mice in which GM-CSF is expressed at increased levels. Protective effects of GM-CSF were observed both in mice with constitutive and inducible GM-CSF expression under the control of the pulmonary-specific SFTPC or SCGB1A1 promoters, respectively. Mice that continuously secrete high levels of GM-CSF developed desquamative interstitial pneumonia that impaired long-term recovery from influenza. Conditional expression of optimal GM-CSF levels at the time of infection, however, resulted in alveolar macrophage proliferation and focal lymphocytic inflammation of distal airways. GM-CSF enhanced alveolar macrophage activity as indicated by increased expression of SP-R210 and CD11c. Infection of mice lacking the GM-CSF-regulated SR-A and MARCO receptors revealed that MARCO decreases resistance to influenza in association with increased levels of SP-R210 in MARCO(-/-) alveolar macrophages. In conclusion, GM-CSF enhances early host resistance to influenza. Targeting of MARCO may reinforce GM-CSF-mediated host defense against pathogenic influenza.

Indexed as

AnimalsFemaleGranulocyte-Macrophage Colony-Stimulating FactorInfluenza A Virus, H1N1 SubtypeLungLymphocytesMacrophagesMaleMiceMice, Inbred C57BLMice, KnockoutOrthomyxoviridae InfectionsSurvival AnalysisGranulocyte-Macrophage Colony-Stimulating Factor

Identifiers

PMID21925209
PMCPMC4894852
OpenAlexW1985556843

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.